Zymeworks (ZYME) The Citizens Life Sciences Conference 2026 summary

Strategic overview and business model

• Focus on developing assets to key inflection points, then partnering for upfront payments and long-term royalties.

• Maintains a royalty aggregation model, leveraging stable income from out-licensed assets to fund internal pipeline and potential acquisitions.

• Recently secured a $250 million royalty note, enhancing financial flexibility and confidence in future royalty streams.

• Current cash position exceeds $500 million, with additional milestone payments expected from regulatory approvals.

• Actively considers acquiring companies or assets with royalty streams to further compound value.

Pipeline highlights and clinical progress

• Zanidatamab, a bispecific HER2 antibody, is advancing in multiple indications, with regulatory filings for first-line GEA and ongoing pivotal trials in breast cancer.

• Early data for zanidatamab in GEA and breast cancer show transformative efficacy and safety, with regulatory approval in the US expected in the second half of the year.

• Pasritamig, a T-cell engager targeting KLK2, is in pivotal studies with J&J, demonstrating manageable safety and promising efficacy.

• ZW191, a folate receptor alpha ADC, shows a wide therapeutic index and early response rates in the 60% range, with additional data expected this year.

• ZW209 (DLL3/CD3/CD28 tri-specific) and ZW418 (PTK7 bi-paratopic ADC) are advancing toward IND filings, with clinical entry planned for 2026.

Financial outlook and upcoming milestones

• Expects $440 million in regulatory milestone royalties for zanidatamab in GEA, plus $90 million for a third indication.

• Breast cancer trial enrollment to complete by year-end, with readout expected by late 2027 or early 2028.

• Pasritamig entering phase 3, and GPC3 ADC in phase 1 with data readouts anticipated by year-end or early next year.

• Plans to bring additional T-cell engagers and an autoimmune molecule into the clinic in 2026.

• Strategic focus for the year includes executing deals to acquire new royalty-generating assets and advancing internal programs.